Faron, etusivu

releases and publications

Faron 2024 Half-Year Financial Results

Regulatory

FDA Grants Fast Track Designation for Bexmarilimab

Regulatory

Notice of Half-Year Financial Results

Regulatory

Traumakine Research Collaboration and DoD Grant

Appointment of Chief Financial Officer

Regulatory

Grant of options

Insider Transaction Regulatory

Faron Appoints Dr. Petri Bono as new CMO

Regulatory

Faron Announces Positive FDA Feedback

Regulatory

Update on settlement

Regulatory

Holding(s) in Company - Replacement

Shareholder announcement Regulatory
PreviousNext
Back to top